MRI-US Image Fusion Prostate Biopsy

Posted by John F. Ward, MD, FACS | Jul 2019

John F. Ward, MD, presented “MRI-US Image Fusion Prostate Biopsy” during the 24th Annual Southwest Prostate Cancer Symposium on April 13, 2019 in Scottsdale, Arizona.

How to cite: Ward, John F. “MRI-US Image Fusion Prostate Biopsy” April 13, 2019. Accessed Apr 2024. https://dev.grandroundsinurology.com/mri-us-image-fusion-prostate-biopsy/

MRI-US Image Fusion Prostate Biopsy – Summary:

John F. Ward, MD, FACS, details the workflow of the ARTEMIS Semi-Robotic Fusion Biopsy System through videos and software demonstrations. He illustrates the movement of the system’s endfire probe, the process of gathering images, rendering a digital 3D model of the prostate, and navigating the placement of biopsy needles.

Abstract:

By using the ARTEMIS Semi-Robotic Fusion Biopsy System, a multiparametric MRI/ ultrasound (MR-US) technology with semi-robotic, electronic-mechanical tracking of the prostate, clinicians can precisely navigate needles to identify lesions and significantly improve the accuracy of biopsy. This presentation provides a step-by-step walkthrough of the biopsy workflow with this system through videos and software demonstrations.

The demonstrations will cover proper maneuvering and positioning of this system’s endfire probe and application of its mechanical arm.

It will also illustrate the system’s utilization of 360 degrees of images gathered from the ultrasound probe and computer-generated prostate contouring, which physicians can refine manually, in order to render a 3D in-silico model of the prostate.

This system works in tandem with ProFuse Radiology Software, which similarly performs 3D modeling of the prostate through MRI, to identify, localize, and map regions of interest (ROIs). The ARTEMIS system can then align and merge this radiologic data with the ultrasound model.

This fused image and in-silico prostate model can then direct the placement of biopsy needles. The system employs motion compensation to match the previously-constructed virtual images and real-time ultrasound images while the physician navigates the needle to a target with the probe and mechanical arm. Not only can this method better target ROIs, it can also help avoid under- and oversampling in systematic biopsies. The system will record the history of exact locations of cores taken, as well. Finally, the system has the ability to import previously-recorded information from a patient, which is beneficial for future biopsies.

About the Southwest Prostate Cancer Symposium

The Southwest Prostate Cancer Symposium (SPCS) is a multi-day conference that seeks to educate urologists, radiation oncologists, medical oncologists, and other healthcare professionals involved in the treatment of prostate cancer. The topics focus on current technical aspects of diagnosis and treatment of localized and advanced disease, particularly regarding imaging, technology, and training in the related devices. Dr. Ward presented this lecture during the 24th SPCS in 2019. In 2020, the 25th SPCS will also offer training sessions involving imaging, scanning, and prostate cancer treatment related devices on site. Please visit this page in order to register for future SPCS meetings.

About The Author

John F. Ward, MD, FACS

John F. Ward, MD, FACS, is an Associate Professor of Urology in the Division of Surgery at the University of Texas MD Anderson Cancer Center in Houston. He is a clinical scientist with exclusive focus on the management of prostate and testicular cancers. He is recognized as one of the early thought leaders in prostate cancer imaging and focal therapy. His contributions laid the groundwork that has helped this approach gain recognition as an acceptable therapeutic strategy for select patients with prostate cancer. He helped develop ablative techniques using a variety of energy and imaging techniques, and was involved in the early studies of interstitial laser ablation, focal cryotherapy, and high-intensity focused ultrasound, the latter work leading to the FDA US approval. He is equally involved in the development of urine and blood biomarkers of prostate cancer, as well as image-guided targeted prostate biopsy. As a busy clinician, Dr. Ward not only pioneered the MD Anderson Cancer Center Prostate Cancer Imaging and Focal Therapy program while performing 200+ robotic assisted prostatectomies a year, but he also developed the MD Anderson technique of robotic retroperitoneal lymph node dissection, and has now expanded this surgery into the post-chemotherapy setting and as primary treatment for metastatic seminoma. A native of Pittsburgh, Pennsylvania, Dr. Ward is a Graduate of the University of Notre Dame and Georgetown Medical School. He received his urologic oncology training at the Mayo Clinic in Rochester, Minnesota, before completing a career with the US Navy. He joined the faculty at MD Anderson Cancer Center in 2006.

Join the GRU Community

- Why Join? -

CARDEN JENNINGS PUBLISHING CO., LTD.

Your GRU

– Account Dashboard
– Your Courses

Recent Updates

PDF Embedder Test Jan 2022
Genetic Testing and Prostate Cancer – Welcome Jan 2022
Current Status of PSMA Diagnostics Aug 2021
Genetic Testing and Prostate Cancer Aug 2021
What’s New in Active Surveillance for Prostate Cancer in 2021 Aug 2021

Exercise & Wellness

Share This